AstraZeneca made $ 275m in value from its unprofitable Covid-19 vaccine in the first quarter, while sales of cancer drugs and growth in the upcoming markets help the manufacturer exceed its profits and expectations.
The pharmaceutical company has confirmed their annual projections for increased income for young people, with profits per capita rising rapidly, to between $ 4.75 and $ 5.
Pascal Soriot, chief executive of AstraZeneca, said the mechanism was even though the epidemic was delaying the diagnosis and treatment of many diseases.
“We have made significant strides in the first phase of 2021 and we have continued to advance our history of life-changing drugs,” he said. “We expect the results of Covid to diminish and we look forward to dismissal in the second quarter of 2021.”
AstraZeneca also reported a refund of $ 7.3bn, excluding the revenue it received from a vaccine it had developed with Oxford University, up to 15% per annum and beyond the agreed $ 7bn.
Sales of oncology increased by 20% from the same period last year, while revenues from incoming markets increased by 14%, with a 19% increase in China.
The peak earnings on the rise rose 55% to $ 1.63, beating readers’ average of $ 1.48.